Home Analyses Company update Cereno Scientific – a rare opportunity in cardiovascular diseases

Company update Cereno Scientific – a rare opportunity in cardiovascular diseases

Company update Cereno Scientific – a rare opportunity in cardiovascular diseases

14 October, 2020

Cardiovascular diseases (CVD) are the most common cause of death in the world. An estimated 17,9 million people are expected to die every year, a figure that is forecasted to rise to 22,2 million by 2030. Gothenburg-based biotech company Cereno Scientific is developing new a new class of therapies in CVD, using an epigenetic modulation platform. Earlier this year, the FDA granted Cereno Scientific orphan drug designation-status (ODD) for its leading clinical phase II candidate CS1 in pulmonary arterial hypertension (PAH). BioStock has now published a company update on Cereno Scientific.

Supported by world leading experts in CVD and PAH, Cereno Scientific’s management recently announced that they will initiate a phase IIa with CS1 in PAH trial by mid 2021. At the same time, the company secured funding through a directed share issue of SEK 60 million and a loan facility of SEK 10 million, allowing them to go forward with their plans.

Advancing CS1 in PAH, is the first step in validating their technology, introducing a new class of treatment in CVD, both rare and common, an area with a growing need for new therapies.

Download BioStock’s status report here.




This analysis is a Status Report by BioStock, conducted on commission by the analysed company. BioStock’s remuneration for the work has been agreed upon beforehand and is independent of the content and conclusions reached in the analysis. The content of this analysis is based solely on publicly available information gathered through research by the analyst from sources such as e.g. financial reports and statements, the company’s web page, public presentations and in dialogue with representatives of the company’s executive management. The information about the company was made available to the company for fact-checking and was published subsequent approval by the company. The analysis contains subjective assessments regarding future events and outcomes which should be considered to render such assessments to be uncertain. Any valuation of the company, products and/or markets has been made by BioStock’s analyst. The analyst does not own shares in the company. This analysis should not be considered as a recommendation or advice to invest in the company nor shall it be interpreted as financial advice of any sort. BioStock can not and does not give any guarantees that the conclusions or forecasts presented in this analysis will be fulfilled. BioStock can not be held responsible or liable for any damage, direct or indirect, caused by decisions made based on the information in this analysis. BioStock is not subject to the oversight of the Swedish financial authority Finansinspektionen and is thus not required to comply with the specific rules and guidelines that apply to analysis firms subject to the oversight of Finansinspektionen.


Prenumerera på BioStocks nyhetsbrev